C3 Glomerulonephritis: A Rare Case of GN

Stanley Linder
Hesham Shaban

Follow this and additional works at: https://scholarlycommons.henryford.com/merf2020caserpt
C3 Glomerulonephritis: A Rare Case of GN

Stanley Linder, D.O. and Heshem Shaban M.D.
Nephrology and Hypertension, Henry Ford Health System, Detroit, Michigan

Introduction

C3 Glomerulonephritis has undergone a recent change in its definition since its consensus review in 2013. Prior to 2013, C3GN would have been classified morphologically as a Type 3 Membranoproliferative Glomerulonephritis with the classic pathologic feature of double contoured Basement Membrane which is notable in all MPGN types. It is relatively rare phenomenon affecting 1-2/1,000,000 cases in the US, based on registry data involving an overactivation of the Alternative Complement System.

Case

A 71 year old woman with a past medical history of Hepatitis C with more than 1.5 million viral copies was admitted with lower extremity edema, urinary retention, and CHF exacerbation with notable sacral edema. The admission also resulted in an acute kidney injury which was initially thought to be a component of aggressive diuresis. Nephrology was consulted and urine studies were obtained. The patient was noted to have nephrotic range proteinuria over 8 grams/gram and hematuria. Glomerulonephritis was a major concern given her Hepatitis C diagnosis. Serologies were obtained. Laboratory studies were consistent with a possible Cryoglobulinemic Glomerulonephritis with undetectable C4 levels, low C3 levels, and an elevated Rheumatoid Factor. While waiting for Cryoglobulin levels to return, the patient underwent a kidney biopsy to confirm the suspected diagnosis.

Biopsy

Results

- Patient was noted to have double contoured BM, increased cellularity and mesangial expansion with capillary wall thickening on LM, Subendothelial humps on EM, and IF positive only for C3
- Noted to have C3 Glomerulonephritis

Case Notes

- Eculizumab for treatment of rapidly progressive C3 glomerulopathy
- Investigational drug trials into Eculizumab have not shown success
- Noted to have C3 Glomerulonephritis
- Current treatments include supportive care with BP goal <120/80, RAAS Blockage with ACEI/ARB for all patients.
- Subset of patients with >500mg/24h urinary protein or progression of disease are treated with immunosuppression with MMF and steroids
- Investigations into therapeutics that can block C3
- Investigational drug trials into Eculizumab have not shown success
- Despite current available treatments, progression to ESRD after 10 years following diagnosis is about 50%
- Investigations into KTx in ESRD secondary to C3GN had high likelihood of disease recurrence and possible graft loss
- Further investigations into therapeutics that can block C3

Conclusion

- Illustrates the necessity of a kidney biopsy to confirm the diagnosis of a suspected glomerulonephritis
- Overactive Complement System
- All have different points of origin but converge at C3 to activate the Terminal Complement Cascade giving rise to MAC Complex and Cell Lysis
- Current treatments include supportive care with BP goal <120/80, RAAS Blockage with ACEI/ARB for all patients.
- Subset of patients with >500mg/24h urinary protein or progression of disease are treated with immunosuppression with MMF and steroids
- Investigational drug trials into Eculizumab have not shown success
- Despite current available treatments, progression to ESRD after 10 years following diagnosis is about 50%
- Investigations into KTx in ESRD secondary to C3GN had high likelihood of disease recurrence and possible graft loss
- Further investigations into therapeutics that can block C3

Electron Microscopy

- Subendothelial humps usually seen in C3 Glomerulonephritis
- EM required to differentiate between C3GN and DDD

C3 Immunostaining with 2+ Florescence

- IF required to diagnose C3 Glomerulopathy

References